Interferon beta (IFNb) is a safe first-line drug commonly used for relapsing-remitting (RR)-MS. Nevertheless, a considerable proportion of patients do not respond to IFNb treatment. Therefore, until now, a number of studies have investigated various markers that could predict the patients who would respond to IFNb therapy. The objective of this study was to identify reliable biomarkers to predict the efficacy of IFNb treatment in MS.
Stampanoni Bassi, M., Drulovic, J., Pekmezovic, T., Iezzi, E., Sica, F., Gilio, L., et al. (2020). Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 13, 1756286420970833 [10.1177/1756286420970833].
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients
Gentile, Antonietta;Musella, Alessandra;Marfia, Girolama Alessandra;Centonze, Diego;Buttari, Fabio
2020-01-01
Abstract
Interferon beta (IFNb) is a safe first-line drug commonly used for relapsing-remitting (RR)-MS. Nevertheless, a considerable proportion of patients do not respond to IFNb treatment. Therefore, until now, a number of studies have investigated various markers that could predict the patients who would respond to IFNb therapy. The objective of this study was to identify reliable biomarkers to predict the efficacy of IFNb treatment in MS.| File | Dimensione | Formato | |
|---|---|---|---|
|
1756286420970833.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
181.77 kB
Formato
Adobe PDF
|
181.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
